An FDA panel is scheduled to review Takeda Pharmaceutical Co. Ltd.’s (TAK) New Drug Application for Maribavir on October 7, 2021.Maribavir is an investigational antiviral agent for the treatment of post-transplant recipients with cytomegalovirus (CMV) infection in those resistant and/or refractory to prior anti-CMV treatment.Cytomegalovirus (CMV) is a beta herpesvirus that commonly infects humans. Out of the estimated 200,000 adult transplants per year, CMV is one of the most common viral infections experienced by transplant recipients. In transplant recipients, reactivation of CMV can lead to serious consequences including loss of the transplanted organ and, in extreme cases, can be fatal.Antiviral therapies like Ganciclovir and Valganciclovir are used primarily in treating CMV infection. If approved, Maribavir will be the first and only treatment indicated for post-transplant CMV infection in those that are refractory, with or without resistance.The final FDA decision on Maribavir is expected to be announced on November 21, 2021.The global sales for Maribavir could exceed $7 million by 2027, according to GlobalData.TAK closed Wednesday’s trading at $16.31, down 1.75%.